Abraxane White Paper Distribution At ASCO Draws FDA Advertising Letter
This article was originally published in The Pink Sheet Daily
Celgene says the white paper – which FDA says promotes Abaxane as effective for unapproved uses and superior to Bristol-Myers Squibb’s Taxol – was intended solely for potential business partners interested in nab technology.
You may also be interested in...
The Vice President’s cancer “moonshot” is a great opportunity for biopharma companies to engage in a process that should remind policymakers and the public of the promise of biomedical innovation at a time when the industry’s pricing and financial engineering activities are under scrutiny on Capitol Hill. The selection of the “blue ribbon” panel puts those two images in stark contrast.